Adenoviral-Vector-Gene-Therapy

Replication-defective adenoviral vectors that deliver vaccine antigens and therapeutic genes at industrial scale — platform families validated in pandemic trials, suspension bioreactors to 2,000 L, and the plasmid-to-vector GMP chain that feeds them. The table carries four vendors whose dossier ledgers carry full source trails.